Quintiles, which recently went private and has been looking to reduce debt, is selling its Bioglan Pharmaceuticals subsidiary.
Quintiles gets $183 million in cash plus the costs for products in inventory from Bradley Pharmaceuticals, which is based in New Jersey.
The Triangle Business Journal reported that Quintiles acquired Bioglan for $53.7 million.
Bioglan developed dermatology products.
Quintiles: www.quintiles.com
